AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume Increase - Time to Buy?

Key Points

• ABCL shares rose 5.1% to approximately $10.53, with 5.34 million shares traded, although volume declined 13% from the prior session.
• Positive Phase 2 results for ABCL635, an oversubscribed $200 million financing, and Truist’s price-target increase from $12 to $30 have strengthened investor sentiment and the company’s pipeline outlook.
• Despite a “Moderate Buy” consensus and average price target of $12.83, AbCellera remains unprofitable: its latest quarterly loss exceeded expectations, revenue came in below forecasts, and analysts project a full-year loss.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) shares saw strong trading volume on Thursday . 5,340,846 shares traded hands during trading, a decline of 13% from the previous session's volume of 6,108,420 shares.The stock last traded at $10.5270 and had previously closed at $10.35.

More AbCellera Biologics News

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results for ABCL635 in menopausal symptoms represent a significant validation of AbCellera’s internal drug-development strategy and have strengthened the company’s pipeline outlook. AbCellera Phase 2 clinical data
• Positive Sentiment: Truist raised its price target on AbCellera from $12 to $30 and reiterated a “buy” rating, while other coverage cited a fair-value lift following the clinical data and a Jazz Pharmaceuticals deal. The higher targets support continued investor enthusiasm, though they remain analyst opinions rather than guaranteed outcomes. Truist price target
• Positive Sentiment: AbCellera’s $200 million financing was described as oversubscribed, indicating substantial demand from investors and providing additional capital to advance its pipeline and platform activities. AbCellera offering pricing announcement

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ABCL shares. Wall Street Zen lowered AbCellera Biologics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Truist Financial lifted their price target on AbCellera Biologics from $12.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday. Stifel Nicolaus boosted their price target on AbCellera Biologics from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Benchmark raised shares of AbCellera Biologics from a "hold" rating to a "buy" rating and set a $11.00 price objective on the stock in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $12.83.

AbCellera Biologics Trading Up 5.1%

The company's fifty day moving average is $6.45 and its 200-day moving average is $4.81. The firm has a market capitalization of $3.33 billion, a P/E ratio of -20.09 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). The business had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. On average, equities research analysts anticipate that AbCellera Biologics Inc. will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ABCL. SEB Asset Management AB bought a new stake in AbCellera Biologics in the first quarter valued at $1,188,000. Virtu Financial LLC bought a new position in AbCellera Biologics during the 4th quarter valued at about $619,000. Hsbc Holdings PLC lifted its holdings in AbCellera Biologics by 375.4% during the 4th quarter. Hsbc Holdings PLC now owns 117,031 shares of the company's stock valued at $401,000 after purchasing an additional 92,414 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in AbCellera Biologics in the first quarter valued at about $46,000. Finally, Ground Swell Capital LLC bought a new stake in AbCellera Biologics during the first quarter worth about $55,000. Institutional investors and hedge funds own 61.42% of the company's stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source